Education
About Us
Working with TipRanks
Follow Us
James Samuel Shannon Insider Profile
4 Followers
James Samuel Shannon, Director at MannKind, holds 0.00 shares in Horizon Therapeutics (Ticker: HZNP), holds 12.74K shares in MannKind (Ticker: MNKD), holds ― shares in Xilio Therapeutics (Ticker: XLO).
James Samuel Shannon has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that James Samuel Shannon holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by James Samuel Shannon
James Samuel Shannon's Trading History
MannKind
Jun 02, 2015
Director
Uninformative Buy
―
$63.44K
Horizon Therapeutics
Oct 06, 2023
―
Uninformative Sell
6.62M
$0.00
Xilio Therapeutics
―
Director
―
―
Endocyte
―
―
―
$0.00
List of latest transactions for each holding click on a transaction to see James Samuel Shannon's performance on stock
You May Also Like
James Samuel Shannon insider profile FAQ
What is the percentage of profitable transactions made by James Samuel Shannon?
The percentage of profitable transactions made by James Samuel Shannon is ―.
What is the average return per transaction made by James Samuel Shannon?
The average return per transaction made by James Samuel Shannon is ―.
What stocks does James Samuel Shannon hold?
James Samuel Shannon holds: MNKD, HZNP, XLO, ECYT stocks.
What was James Samuel Shannon’s latest transaction?
James Samuel Shannon latest transaction was an Uninformative Sell of $6.62M.
What was James Samuel Shannon's most profitable transaction?
James Samuel Shannon’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is James Samuel Shannon's role in MannKind?
James Samuel Shannon's role in MannKind is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.